Manappuram Finance Limited has announced that Chief Executive Officer Deepak Reddy will take medical leave of absence for overseas treatment, effective February 25, 2026. The company disclosed this information to stock exchanges under regulatory compliance requirements.

Medical Leave Details

The CEO has informed the company of his need for medical treatment abroad, requiring an extended absence from his duties. The leave duration is expected to range from 90 to 120 days, with the exact timeframe dependent on treatment progression.

Regulatory Compliance

The disclosure has been made pursuant to Regulations 30, 51 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As CEO and Key Managerial Personnel of the company, Reddy's medical leave constitutes material information requiring disclosure to stock exchanges.

The company has notified the following exchanges:

• BSE Limited (Scrip Code: 531213)
• National Stock Exchange of India Limited (Scrip Code: MANAPPURAM)
• India International Exchange (IFSC) Ltd

Documentation and Transparency

The intimation has been uploaded on the company's official website at manappuram.com under the disclosure section, ensuring transparency and compliance with listing regulations. Company Secretary Manoj Kumar VR has signed the official communication to the exchanges, confirming the authenticity of the disclosure.

The announcement follows standard corporate governance practices for publicly listed companies when key management personnel require extended leave for medical reasons.

Manappuram Finance Limited has secured a crucial regulatory milestone with the Reserve Bank of India (RBI) granting final approval for a significant investment proposal by BC Asia Investments. The approval, communicated on February 13, 2026, paves the way for one of the largest stake acquisitions in the non-banking financial company sector.

Investment Structure and Approval Details

The RBI has approved the proposed acquisition by two entities - BC Asia Investments XXV Limited (Investor 1) and BC Asia Investments XIV Limited (Investor 2). The approval encompasses the acquisition of control and shareholding of up to 41.66% of Manappuram Finance's paid-up equity capital and convertible instruments.

Regulatory Conditions and Requirements

The RBI approval comes with specific conditions that the investors must adhere to. Any future acquisition by the proposed investors that results in crossing 26% of the paid-up share capital (excluding warrant conversions from the current investment) will require prior RBI approval after one year as prescribed.

Additionally, Manappuram Finance must ensure the investors provide an action plan to the RBI within the specified timeline. This plan must guarantee that there will not be more than one non-banking financial company of the same category or housing finance company within their group with majority shareholding and control.

Pending Approvals and Transaction Timeline

Despite the main approval, the transaction's completion remains contingent on additional regulatory clearances. The RBI approval for subsidiary companies Asirvad Micro Finance Limited and Manappuram Home Finance Limited is still pending.

Open Offer Compliance

The investment will trigger a mandatory open offer by the investors and other identified persons acting in concert with BC Asia Investments XXV Limited. This open offer to public shareholders complies with Regulation 3 and Regulation 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The company has maintained transparency throughout the process, with previous intimations dated March 20, 2025, June 25, 2025, August 27, 2025, and September 17, 2025, keeping stakeholders informed about the transaction's progress. The consummation of the investment and completion of the open offer remain subject to satisfaction of contractual conditions agreed with the investors under the securities subscription agreement dated March 20, 2025.